155 related articles for article (PubMed ID: 38534127)
1. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
Garza K; Aminpour E; Shah J; Mehta B; Early D; Gyawali CP; Kushnir V
Am J Gastroenterol; 2024 Jun; 119(6):1081-1088. PubMed ID: 38534127
[TBL] [Abstract][Full Text] [Related]
2. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
4. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
Kobori T; Onishi Y; Yoshida Y; Tahara T; Kikuchi T; Kubota T; Iwamoto M; Sawada T; Kobayashi R; Fujiwara H; Kasuga M
J Diabetes Investig; 2023 Jun; 14(6):767-773. PubMed ID: 36919944
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
[TBL] [Abstract][Full Text] [Related]
7. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
8. Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy.
Yao R; Gala KS; Ghusn W; Abboud DM; Wallace FK; Vargas EJ
Am J Gastroenterol; 2024 Jun; 119(6):1154-1157. PubMed ID: 37856247
[TBL] [Abstract][Full Text] [Related]
9. Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
Suzuki Y; Kaneko H; Nagasawa H; Okada A; Fujiu K; Jo T; Takeda N; Morita H; Nishiyama A; Gohda T; Suzuki Y; Node K; Yasunaga H; Nangaku M; Komuro I
Diabetes Obes Metab; 2024 Jun; 26(6):2422-2430. PubMed ID: 38528820
[TBL] [Abstract][Full Text] [Related]
10. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF; Kushner P; Aguilar R
Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
[TBL] [Abstract][Full Text] [Related]
11. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
[TBL] [Abstract][Full Text] [Related]
12. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
13. Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist.
Anazco D; Fansa S; Hurtado MD; Camilleri M; Acosta A
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1333-1335.e2. PubMed ID: 38043694
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
[TBL] [Abstract][Full Text] [Related]
15. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
Milder DA; Milder TY; Liang SS; Kam PCA
Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Banerjee M; Pal R; Mukhopadhyay S; Nair K
J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
[TBL] [Abstract][Full Text] [Related]
18. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
19. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
Albèr A; Brønden A; Knop FK
Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]